AI Article Synopsis

  • Two new isostructural complexes, I (cobalt) and II (nickel), were synthesized through solvothermal methods using a compound featuring carboxyphenoxy and terephthalate ligands.
  • Both complexes were thoroughly analyzed using various techniques, including IR spectroscopy, X-ray diffraction, and thermogravimetric analyses, revealing their distinct two-dimensional structures.
  • Magnetic studies showed that both complexes exhibit antiferromagnetic interactions, with specific distances between the metal centers being related to their structural configurations.

Article Abstract

Two new isostructural complexes, namely, poly[aqua[μ-2-(4-carboxyphenoxy)terephthalato-κO:O:O](1,10-phenanthroline-κN,N')cobalt(II)], [Co(CHO)(CHN)(HO)] or [Co(μ-Hcpota)(phen)(HO)], I, and poly[aqua[μ-2-(4-carboxyphenoxy)terephthalato-κO:O:O](1,10-phenanthroline-κN,N')nickel(II)], [Ni(CHO)(CHN)(HO)] or [Ni(μ-Hcpota)(phen)(HO)], II, have been synthesized by solvothermal reactions. Complexes I and II were fully characterized by IR spectroscopy, elemental analyses, thermogravimetric analyses, and powder and single-crystal X-ray diffraction. They both present two-dimensional structures based on [M(μ-COO)] (M = Co or Ni) dinuclear metal units with a fes topology and a vertex symbol (4·8). Interestingly, the positions of the two dimeric metal motifs and the two partially deprotonated Hcpota ligands reproduce regular flying butterfly arrangements flipped upside down and sharing wings in the ab plane. Magnetic studies indicate antiferromagnetic interactions (J = -5.21 cm for I and -11.53 cm for II) in the dimeric units, with Co...Co and Ni...Ni distances of 4.397 (1) and 4.358 (1) Å, respectively, that are related to double syn-anti carboxylate bridges.

Download full-text PDF

Source
http://dx.doi.org/10.1107/S2053229621012973DOI Listing

Publication Analysis

Top Keywords

syntheses structures
4
structures magnetic
4
magnetic properties
4
properties co/ni
4
co/ni isostructural
4
isostructural coordination
4
coordination polymers
4
polymers based
4
based asymmetric
4
asymmetric semirigid
4

Similar Publications

Drug Development.

Alzheimers Dement

December 2024

Yonsei University, Incheon, Incheon, Korea, Republic of (South).

Background: As amyloid-β (Aβ) aggregates are considered as the biomarkers and key factors in the pathology of Alzheimer's disease, there has been extensive investigation into Aβ-targeting compounds for the development of diagnostics and drug discovery related to the disorder. However, the polymorphic and heterogenous nature of Aβ aggregates impedes the structural understanding of their structure. Consequently it is a major challenge to develop new diagnostic and therapeutic development of AD and to study the mechanism of Aβ-targeting compounds.

View Article and Find Full Text PDF

Background: The TREAT-AD centers aim to improve Alzheimer's Disease (AD) research by offering free, high-quality tools and technologies. Lyn is a tyrosine kinase that belongs to the Src family kinases. The expression of Lyn and its activity have been implicated in AD.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

Chitkara College of Pharmacy, Chitkara University, Rajpura, Punjab, India.

Background: The present study recapitulates the potency of the novel synthesized piperazine-benzoquinone derivative as a lead molecule selectively targeting AChE along with the antioxidative potential for the management of cognitive decline in Alzheimer's disease.

Method: Novel piperazine-benzoquinone derivative was synthesized implementing appropriate synthetic procedures and was characterized by various spectral and elemental techniques. The purity of this synthetic analogue was ascertained by TLC, melting point determination and elemental analyses.

View Article and Find Full Text PDF

Background: SHIP1 is a phosphatidyl inositol phosphatase encoded by INPP5D, which has been identified as a risk gene for Alzheimer's disease (AD). SHIP1 is expressed in microglia, the resident macrophage in brain. It is a complex, multidomain protein that acts as a negative regulator downstream from TREM2.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

Theme Inflammation and Aging, Karolinska University Hospital, Stockholm, Sweden.

Background: Alzheimer disease (AD) is a progressive neurodegenerative disease that is accountable for the leading case of dementia in elder people. Before, only symptomatic treatments are available for AD. Since 2021, two anti-amyloid antibodies aducanumab and lecanemab have been approved by the US Food and Drug Administration.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!